Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck collaboration — Eisai Co., Ltd. (Lenvima Oncology Alliance) ($M) ($M)
Form 10-Q / 10-K Note 3/4 Collaborative Arrangements
Latest, Q2 2026
13
Period ended Jun 30, 2026
Change on a year earlier
-78.3%
60 in Q2 2025
History
34 quarters
Since Q1 2018
Sources
29
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up collaboration — eisai co., ltd. (lenvima oncology alliance) ($m)
- Eisai Co., Ltd. (Lenvima Oncology Alliance) — Current receivables from partner ($M)281 · Q2 2026
- Eisai Co., Ltd. (Lenvima Oncology Alliance) — Cost of sales profit-sharing & manufacturing ($M)13 · Q2 2026
- Eisai Co., Ltd. (Lenvima Oncology Alliance) — Net R&D cost-sharing expense ($M)0 · Q2 2026
- Eisai Co., Ltd. (Lenvima Oncology Alliance) — Commercialization / SG&A expense sharing ($M)29 · Q2 2026
Cite this data
StockData. (2026). Merck Collaboration — Eisai Co., Ltd. (Lenvima Oncology Alliance) ($M) ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab_eisai
See every metric in the Merck KPI table. Data updated Oct 26, 2026.